샘플 요청 목록

 카트 문의
시장보고서
상품코드
1794506

세계의 근골격계 약제 시장

Musculoskeletal Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 286 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 근골격계 약제 시장은 2030년까지 1,063억 달러에 달할 전망

2024년에 831억 달러로 추정되는 세계의 근골격계 약제 시장은 분석 기간인 2024-2030년에 CAGR 4.2%로 성장하며, 2030년에는 1,063억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 비스테로이드성 항염증약은 CAGR 4.4%를 기록하며, 분석 기간 종료시에는 467억 달러에 달할 것으로 예측됩니다. 질환 조절성 항류머티즘약 부문의 성장률은 분석 기간 중 CAGR 3.0%로 추정됩니다.

미국 시장은 226억 달러, 중국은 CAGR 7.7%로 성장 예측

미국의 근골격계 약제 시장은 2024년에 226억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 218억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 7.7%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.7%와 3.3%로 예측됩니다. 유럽에서는 독일이 CAGR 2.4%로 성장할 것으로 예측됩니다.

세계의 근골격계 약제 시장 - 주요 동향과 촉진요인 정리

근골격계 약물이 만성질환 관리의 중심이 되는 이유는 무엇인가?

근골격계 약물은 뼈, 관절, 근육, 힘줄, 인대에 영향을 미치는 광범위한 증상의 치료에 필수적입니다. 예를 들어 골관절염, 류마티스 관절염, 골다공증, 강직성 척추염, 통풍, 근육경련 등입니다. 인구가 고령화되고 앉아서 생활하는 것이 일반화됨에 따라 전 세계에서 근골격계 질환에 대한 부담은 계속 증가하고 있습니다. 이러한 질환은 종종 만성 통증, 운동 능력 저하, 신체 장애로 이어지기 때문에 약리학적 치료는 장기적인 관리와 삶의 질 향상을 위한 중요한 요소가 되고 있습니다.

치료 요법에는 진통제, 항염증약, 코르티코스테로이드, 질병 변형 항류마티스제(DMARDs), 근이완제, 골흡수억제제 등이 포함됩니다. 염증성 질환이나 자가면역질환의 경우, 질환의 진행을 늦추기 위해 면역억제요법이나 생물학적 요법이 필요합니다. 골관절염과 같은 퇴행성 질환에서는 통증 조절과 관절 기능에 중점을 둡니다. 치료 목표가 증상 완화에서 기능 회복 및 질병 개선으로 이동함에 따라 보다 효과적이고 표적화된 약물 옵션에 대한 수요가 증가하고 있습니다.

근골격계 약물의 상황을 바꾸고 있는 치료법의 발전은 어떤 것이 있는가?

생물제제 및 표적 합성 DMARDs는 류마티스 관절염, 건선성 관절염과 같은 염증성 근골격계 질환의 치료 성적을 크게 향상시켰습니다. 종양괴사인자(TNF), 인터류킨-6, 야누스 키나아제(JAK) 경로를 억제하는 약물은 면역매개성 관절장애와 전신 염증 조절에 도움을 주고 있습니다. 이러한 치료법은 최적의 조절을 위해 기존 약물과 병용하는 경우가 많으며, 질환의 초기 단계부터 사용되기 시작했습니다.

골다공증에서는 새로운 항골흡수제나 동화제가 골절 예방과 골밀도 개선에 도움을 주고 있습니다. RANK 리간드나 스클레로스틴을 표적으로 하는 단클론 항체는 특히 고위험군이나 치료 불내성 환자에서 임상적으로 인정받고 있습니다. 서방형 제제나월1회 또는 연 2회 주사를 통해 순응도가 향상되었습니다. 저분자 억제제, 재생 화합물, 유전자 기반 치료법에 대한 연구가 진행 중이며, 퇴행성 질환에서 조직 분해를 역전시키거나 근골격계 수리를 지원하는 것을 목표로 하고 있습니다.

시장 수요를 형성하고 있는 환자군과 헬스케어 동향은?

노인 인구의 관절염, 골다공증, 척추 질환의 높은 유병률로 인해 노년층이 가장 큰 사용자 기반을 차지하고 있습니다. 폐경 후 여성은 뼈 건강 제품의 주요 사용자층입니다. 특히 근골격계 문제가 업무 생산성과 일상 기능에 영향을 미치는 도시화 사회에서 만성 요통과 관절 퇴행성 질환을 앓고 있는 현역 세대도 지속적인 수요에 기여하고 있습니다.

소아청소년 관절염이나 유전성 근골격계 질환을 앓고 있는 소아 및 청소년 환자는 전문적인 치료 프로토콜이 필요합니다. 스포츠 의학에서는 근이완제와 항염증약를 사용하여 연부조직의 손상을 관리하고 회복을 촉진하는 데 사용합니다. 의료 시스템은 조기 진단, 위험 계층화, 물리치료 및 약리학적 지원을 포함한 장기적인 질병 관리 프로그램을 추진하고 있습니다. 일반인들의 의식 향상과 셀프케어 문화도 시판되는 진통제나 관절 보조제 사용을 부추기고 있습니다.

근골격계 약물 시장의 성장은 몇 가지 요인에 의해 주도됩니다.

근골격계 의약품 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 관절염, 골다공증, 만성 요통의 유병률 증가로 인해 장기적인 약리학적 관리의 필요성이 대두되고 있습니다. 생물제제 및 표적치료제의 발전으로 자가면역질환 및 염증성 질환에 대한 치료 옵션이 개선되고 있습니다. 인구의 고령화와 평균수명 연장으로 만성기 의료 분야가 확대됩니다. 병용요법 및 장기지속형 제제의 사용이 증가하여 순응도와 치료 성적이 향상됩니다. 뼈와 관절 건강에 대한 대중의 인식이 높아지고 진단에 대한 접근성이 개선되어 조기 개입이 촉진됩니다. 새로운 약물에 대한 규제 당국의 승인과 치료 가이드라인의 확대는 세계 시장 확대를 더욱 촉진할 것입니다.

부문

약제 클래스(비스테로이드성 항염증약, 질환 조절성 항류머티즘약, 진통제, 코르티코스테로이드, 기타 약제 클래스별), 유통 채널(병원 약국, 소매 약국, 온라인 유통 채널)

조사 대상 기업의 예

  • AbbVie Inc.
  • Acorda Therapeutics
  • Astellas Pharma Inc.
  • Biogen Inc.
  • Boehringer Ingelheim
  • Bristol Myers Squibb Co.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi S.A.
  • Sorrento Therapeutics Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

AI 통합

당사는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.28

Global Musculoskeletal Drugs Market to Reach US$106.3 Billion by 2030

The global market for Musculoskeletal Drugs estimated at US$83.1 Billion in the year 2024, is expected to reach US$106.3 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Nonsteroidal Anti-Inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$46.7 Billion by the end of the analysis period. Growth in the Disease Modifying Anti-Rheumatic Drugs segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$22.6 Billion While China is Forecast to Grow at 7.7% CAGR

The Musculoskeletal Drugs market in the U.S. is estimated at US$22.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$21.8 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Musculoskeletal Drugs Market - Key Trends & Drivers Summarized

Why Do Musculoskeletal Drugs Remain Central to Chronic Disease Management?

Musculoskeletal drugs are essential for treating a wide range of conditions that affect bones, joints, muscles, tendons, and ligaments. These include osteoarthritis, rheumatoid arthritis, osteoporosis, ankylosing spondylitis, gout, and muscle spasms. As populations age and sedentary lifestyles become more common, the global burden of musculoskeletal disorders continues to grow. These conditions often lead to chronic pain, reduced mobility, and disability, making pharmacological treatment a critical component of long-term management and quality-of-life improvement.

Treatment regimens include analgesics, anti-inflammatory agents, corticosteroids, disease-modifying antirheumatic drugs (DMARDs), muscle relaxants, and bone resorption inhibitors. Inflammatory and autoimmune conditions require immunosuppressive or biologic therapies to slow disease progression. For degenerative conditions such as osteoarthritis, the focus remains on pain control and joint function. As treatment goals shift from symptom relief to functional restoration and disease modification, demand is rising for more effective, targeted drug options.

What Therapeutic Advances Are Transforming the Musculoskeletal Drug Landscape?

Biologic and targeted synthetic DMARDs have significantly improved outcomes in inflammatory musculoskeletal diseases such as rheumatoid arthritis and psoriatic arthritis. Agents that inhibit tumor necrosis factor (TNF), interleukin-6, or Janus kinase (JAK) pathways help control immune-mediated joint damage and systemic inflammation. These therapies are increasingly used earlier in the disease course, often in combination with conventional agents for optimal control.

In osteoporosis, newer antiresorptive and anabolic drugs are offering better fracture prevention and bone density improvement. Monoclonal antibodies targeting RANK ligand or sclerostin have gained clinical acceptance, especially among high-risk or treatment-intolerant patients. Extended-release formulations and once-monthly or biannual injections are improving adherence. Research into small molecule inhibitors, regenerative compounds, and gene-based therapies is underway, aiming to reverse tissue degradation or support musculoskeletal repair in degenerative diseases.

Which Patient Populations and Healthcare Trends Are Shaping Market Demand?

Older adults represent the largest user base due to the high prevalence of arthritis, osteoporosis, and spinal disorders in aging populations. Women post-menopause form a key demographic for bone health products. Working-age individuals affected by chronic back pain or joint degeneration also contribute to sustained demand, particularly in urbanized societies where musculoskeletal issues impact work productivity and daily function.

Pediatric and adolescent patients with juvenile arthritis or genetic musculoskeletal conditions require specialized treatment protocols. In sports medicine, muscle relaxants and anti-inflammatory drugs are used to manage soft tissue injuries and promote recovery. Healthcare systems are increasingly promoting early diagnosis, risk stratification, and long-term disease management programs, including physical therapy and pharmacological support. Rising public awareness and self-care culture are also encouraging over-the-counter use of pain relievers and joint health supplements.

Growth in the Musculoskeletal Drugs Market Is Driven by Several Factors…

Growth in the musculoskeletal drugs market is driven by several factors. Rising incidence of arthritis, osteoporosis, and chronic back pain increases the need for long-term pharmacological management. Advances in biologics and targeted therapies provide improved treatment options for autoimmune and inflammatory disorders. Aging populations and extended life expectancy expand the chronic care segment. Increased use of combination therapies and long-acting formulations improves adherence and treatment outcomes. Greater public awareness of bone and joint health, along with improved diagnostic access, boosts early intervention. Regulatory approvals for novel agents and expanding treatment guidelines further support market expansion globally.

SCOPE OF STUDY:

The report analyzes the Musculoskeletal Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids, Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Acorda Therapeutics
  • Astellas Pharma Inc.
  • Biogen Inc.
  • Boehringer Ingelheim
  • Bristol Myers Squibb Co.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi S.A.
  • Sorrento Therapeutics Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Musculoskeletal Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Burden of Musculoskeletal Disorders Drives Demand for Targeted Drug Therapies
    • Aging Population Worldwide Throws Spotlight on Osteoarthritis, Rheumatoid Arthritis, and Osteoporosis Treatment Needs
    • Advancements in Biologics and Biosimilars Expand Options in Chronic Inflammatory Musculoskeletal Conditions
    • Increasing Incidence of Back Pain and Sports Injuries Spurs Use of Analgesics, NSAIDs, and Muscle Relaxants
    • Pharmaceutical Innovation in Disease-Modifying Agents Strengthens Long-Term Management of Joint Disorders
    • Growth in Orthopedic Surgical Interventions Creates Demand for Postoperative Pain and Inflammation Control
    • Regulatory Approvals of Injectable Therapies and Long-Acting Drug Formulations Improve Patient Compliance
    • Rising Demand for Personalized and Stratified Treatment Approaches Drives Precision Drug Development
    • Improved Access to Specialty Clinics and Rheumatologists Enhances Early Diagnosis and Pharmacological Intervention
    • Integration of Digital Therapeutics and Remote Monitoring Tools Supports Adherence in Long-Term Therapy
    • Increased Use of Nutraceuticals and Adjunct Therapies Promotes Combined Drug and Lifestyle-Based Interventions
    • Global Expansion of Healthcare Coverage and Reimbursement Schemes Promotes Accessibility of Branded and Generic Drugs
    • Growing Awareness of Musculoskeletal Health Among Working Adults Drives Preventive Use of OTC Products
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Musculoskeletal Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Musculoskeletal Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Musculoskeletal Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Nonsteroidal Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Nonsteroidal Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Nonsteroidal Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Disease Modifying Anti-Rheumatic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Disease Modifying Anti-Rheumatic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Disease Modifying Anti-Rheumatic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Musculoskeletal Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Musculoskeletal Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Musculoskeletal Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Musculoskeletal Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Musculoskeletal Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Musculoskeletal Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Musculoskeletal Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Musculoskeletal Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Musculoskeletal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Musculoskeletal Drugs by Drug Class - Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Musculoskeletal Drugs by Drug Class - Percentage Breakdown of Value Sales for Nonsteroidal Anti-Inflammatory Drugs, Disease Modifying Anti-Rheumatic Drugs, Analgesics, Corticosteroids and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Musculoskeletal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Musculoskeletal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제